Daily Newsletter

14 February 2024

Daily Newsletter

14 February 2024

Gilead aims to cash in on liver disease wave with $4.6bn CymaBay deal

Gilead announced its $4.6bn acquisition of CymaBay will see it gain an advanced primary biliary cholangitis (PBC) candidate, as it aims to follow the success of Ocaliva.

Akosua Mireku February 13 2024

Gilead Sciences declared its $4.3bn acquisition of the liver disease company CymaBay Therapeutics, thereby gaining CymaBay’s lead candidate seladelpar, a treatment for PBC, including pruritus.

Following the 12 February announcement, CymaBay’s stocks soared by more than 25% while Gilead, whose market cap is $94.2bn, also saw a stock price increase of 1.1%.

The companies plan to close the deal during the first quarter of 2024. After closing the deal, Gilead will claim all remaining shares not tendered, in a second-step merger at the same price as in the tender offer. Furthermore, if the US Food and Drug Administration (FDA) approves seladelpar, Gilead predicts that the transaction will become approximately neutral to earnings per share in 2025 and will continue growing the company’s revenue thereafter.

PBC is an autoimmune disorder that causes the bile ducts to become inflamed and slowly deteriorate. If approved, it will become the second treatment available to patients with PBC, after the FDA granted Intercept approval for Ocaliva (obeticholic acid), in 2016. Since the approval, Alfasigma has gained ownership of the therapy through a November 2023 acquisition.

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that regulates the genes involved in lipid storage and transport. Ocaliva, an oral farnesoid X receptor (FXR) agonist, acts by repairing the regulation of cholesterol and bile acid homeostasis, preventing fibrosis.

Alongside the deal news, CymaBay announced that the FDA had accepted its new drug application (NDA) for seladelpar, giving it a priority review. The therapy’s Prescription Drug User Fee Act (PDUFA) date has been set to 14 August 2024, with no plans to hold an advisory committee for the approval decision. The NDA takes into account data from the Phase III RESPONSE (NCT04620733) and ENHANCE (NCT03602560) studies, the ASSURE study (NCT03301506), and previous Phase II studies.

The deal follows a successful financial year for Gilead in 2023. Last year, the California-based company achieved a 22.9% increase in net income, reaching $5.61bn in net income compared to $4.56bn in 2022. Despite a 1% reduction in the company’s total sales, falling to $27.11bn, the pharma giant maintained growth through a reduction in intellectual property and research and development impairment expenses among other things.

CymaBay’s seladelpar programme will now join Gilead’s pipeline, consisting of 55 clinical programs. This includes 14 Phase I studies, 26 Phase II studies, 13 Phase III studies, and two registrational trials. Seladelpar is Gilead’s first clinical asset in development for PBC.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close